Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Abstract

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38–1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80–3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.

Finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants

“…The significant decline of nAb response against the delta variant observed among post 3 months’s BNT162b2 vaccinees in our study provides a possible reason for the increased breakthrough infections observed globally. The report that BNT162b2 recipients who completed their vaccination between Jan-April in Israel had an increased risk of breakthrough infections with delta variant is in line with our interpretation 29 . Thus, our test’s ability to detect variant specific nAb waning effects among a vaccinated population provides an extremely valuable tool to pre-emptively test nAb responses against emerging variants and through this inform booster planning and public health management.…”

Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease

“…A high incidence of breakthrough infection among vaccinated healthcare workers and the general population has also been described. 7,8 As such, the ACIP recommended a booster mRNA vaccine dose six months following completion of the original two-dose vaccine series for all adults. Booster doses have reduced incidence of infection and severity of illness.…”

Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study

“…While protection against hospitalizations and deaths remained robust, several studies appeared to show a decline in protection against COVID-19 infections a few months after the initial vaccination. In a retrospective study in Israel, rates of breakthrough infections amongst fully vaccinated patients with the Pfizer-BioNTech vaccine were considerably higher among those vaccinated earlier than those who were immunized later [11]. Analysis of an observational study among fully vaccinated nursing home residents revealed that the vaccine efficacy dropped from 74.7% to only 53.1% in a few months [12].…”